Basic Information
| LncRNA/CircRNA Name | PVT1 |
| Synonyms | PVT1, LINC00079, MYC, NCRNA00079, onco-lncRNA-100 |
| Region | GRCh38_8:127794533-128101253 |
| Ensemble | ENSG00000249859 |
| Refseq | NR_003367 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qPCR, Western blot, RNAi, RIP etc. |
| Sample | cell lines (MHCC-97h, HepG2, QGY7701, QGY7703, BEL7402, Sk-hep1, SMMC-7721 and HL-7702) |
| Expression Pattern | up-regulated |
| Function Description | Our study found that high PVT1 expression in HCC cells is associated with high unmethylation in PVT1 promoter region. IFN-a treatment further increases PVT1 expression in HCC cells by enhancing H3K4me3 modification on the promoter. Furthermore, PVT1 knockdown enhances IFN-a-induced HCC cell apoptosis by promoting phosphorylation of signal transducer and activator of transcription 1 (STAT1) and upregulating IFN-stimulated genes expression. Moreover, PVT1 specifically interacts with STAT1 in HCC cells. Taken together, these results for the first time indicate that IFN-a treatment promotes oncogenic PVT1 expression in HCC cells, which interacts with STAT1 to inhibit IFN-a signaling, ultimately blocking IFN-a-induced cells apoptosis, suggesting that lncRNA PVT1 may be a potential target to improve IFN-a-mediated HCC immunotherapies. |
| Pubmed ID | 29715456 |
| Year | 2018 |
| Title | Long noncoding RNA PVT1 inhibits interferon-a mediated therapy for hepatocellular carcinoma cells by interacting with signal transducer and activator of transcription 1. |
External Links
| Links for PVT1 | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |